Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Feasibility Study of Empagliflozin As Treatment for Idiopathic Pulmonary Arterial Hypertension

NCT05493371 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.

NCT NCT05493371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05493371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Feasibility Study of Empagliflozin As Treatment for Idiopathic Pulmonary Arterial Hypertension
Lead sponsor
Amsterdam UMC, location VUmc
Phase
Phase 2
Overall status
Completed
Start date
March 1, 2023
Completion date
November 1, 2024
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

idiopathic pulmonary arterial hypertension